PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a - Phosphodiesterase-4 inhibitor - Document - PDFSEARCH.IO

First Page	Meta Content
	PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a Add to Reading List Document Date: 2014-05-29 15:15:36 Open Document File Size: 80,86 KB Share Result on Facebook City San Diego / / Company Celgene Corporation / AEs / GE / / Event Person Communication and Meetings / / Facility American College of Rheumatology / / MedicalCondition key inflammatory cytokines / tumor / severe plaque psoriasis / necrosis / severe psoriasis / psoriasis / Ankylosing Spondylitis / Plaque Psoriasis / psoriatic arthritis / immune and inflammatory processes / / Organization the American College / European League Against Rheumatism / Food and Drug Administration / Blanco FJ / / Person Van Rossen / Ann Rheum / / / Position physician / / Product sulfasalazine / Humira / Orencia / Remicade / leflunomide / Enbrel / SC injection / / ProvinceOrState California / / SocialTag Pharmacology Adalimumab Psoriasis Leflunomide Ustekinumab Psoriatic arthritis Etanercept Golimumab Infliximab Immunosuppressants

PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of aAdd to Reading List